SCHEMBL9949158

SCHEMBL9949158

COc1cccc(-c2ocnc2CBr)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.48
NOTUM Q6P988 2/20 0.48
DYRK1A Q13627 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CCNB2 O95067 1/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
GSK3A P49840 1/20 0.41
CDK5 Q00535 1/20 0.41
CDK5R1 Q15078 1/20 0.41
CCNB3 Q8WWL7 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
KMT2A Q03164 2/20 0.40
TP53 P04637 1/20 0.40
NFKB1 P19838 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL244662 0.76 ADORA2A (0.46) GSK3BNOTUMKDM4EALDH1A1HPGD
SCHEMBL9949083 0.76 RXRA (0.46) NOTUMDYRK1ACLK4KDM4ENPC1
SCHEMBL1167103 0.73 GSK3B (0.61) GSK3BNOTUMDYRK1ACLK4ALDH1A1
SCHEMBL9125394 0.72 GSK3B (0.64) GSK3BNOTUMDYRK1ACLK4KDM4E
SCHEMBL9243217 0.72 ADORA2A (0.62) GSK3BNOTUMDYRK1ACLK4ALDH1A1
SCHEMBL15189706 0.71 GSK3B (0.51) GSK3BNOTUMDYRK1ACLK4KDM4E
SCHEMBL6207912 0.69 FYN (0.50) GSK3BNOTUMDYRK1ACLK4KDM4E
SCHEMBL24785078 0.69 CLK4 (0.63) DYRK1ACLK4NPC1RAB9ASMN1; SMN2
SCHEMBL30103025 0.69 CLK4 (0.63) DYRK1ACLK4NPC1RAB9ASMN1; SMN2
2-Mercaptoethanol SCHEMBL11751369 0.69 HSD17B10 (0.47) GSK3BNOTUMDYRK1ACLK4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012101487-A1 DI/TRI-AZA-SPIRO-C9-C11ALKANES NOVARTIS AG (CH) 2012-08-02 WO disclosed
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-06-28 US disclosed
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-06-28 US disclosed
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165331-A1 Di/tri-aza-spiro-C9-C11alkanes TACR2, TACR1, AGTR1 GSK3B 4021/4885NOTUM 3068/4885DYRK1A 1190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.